# US 2022/0276258 A1 · Methods of quantifying frataxin and frataxin fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276258 A1
- Document ID: US20220276258A1
- Status: Published application
- Kind: A1
- Application number: 17/631,414
- Filed: 2020-07-29
- Published: 2022-09-01
- Earliest claimed: 2019-07-29
- Assignees: Larimar Therapeutics, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Applicants: Larimar Therapeutics, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Inventors: Joan David Bettoun; Erik Johan Wagner; Xin Xu; Jean-Nicholas Mess; Amy Qiu Wang
- Web page: https://patentgrep.com/patent/US20220276258A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods for determining the amount of FXN or FXN fusion protein in a sample, e.g, a tissue sample, by using mass spectrometry.

## Claims

### Claim 1

A method for determining the amount of unprocessed frataxin (FXN) fusion protein in a sample, said method comprising determining the amount of a peptide in said sample by using mass spectrometry (MS),
wherein said peptide comprises the amino acid sequence GGMWTLGR (SEQ ID NO: 12); and
wherein said unprocessed FXN fusion protein comprises, from N-terminus to C-terminus, a cell penetrating peptide (CPP); a mitochondrial targeting sequence (MTS) comprising SEQ ID NO: 3; and FXN comprising SEQ ID NO: 2.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample is obtained from a subject being administered the unprocessed FXN fusion protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein said CPP comprises HIV-TAT (SEQ ID NO: 4) or HIV-TAT+M (SEQ ID NO: 15).

### Claim 4 (depends on 2)

The method of claim 2, wherein said unprocessed FXN fusion protein is TAT-GG-FXN (SEQ ID NO: 11).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein said method comprises purifying by immunocapture the unprocessed FXN fusion protein from said sample prior to MS.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein said method comprises the following steps:
a) purifying by immunocapture the unprocessed FXN fusion protein from said sample, thereby obtaining immunocaptured complexes comprising the unprocessed FXN fusion protein;
b) subjecting said immunocaptured complexes comprising the unprocessed FXN fusion protein to digestion by trypsin, thereby producing the peptide comprising SEQ ID NO: 12; and
c) determining the amount of the peptide comprising SEQ ID NO: 12 by liquid chromatography and tandem mass spectrometry (LC/MS-MS).

### Claim 7 (depends on 6)

The method of claim 6, wherein in part c) the liquid chromatography (LC) comprises reversed-phase chromatography.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein tandem mass spectrometry (MS-MS) comprises monitoring the transition 439.2→632.3.

### Claim 9 (depends on 6, 7)

The method of claim 6 or 7, wherein tandem mass spectrometry (MS-MS) comprises monitoring the transition 439.2→446.3.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The method of any one of claims 5-9, wherein the immunocapture is carried out using a binding protein comprising an antigen binding domain that specifically binds to the FXN fusion protein.

### Claim 11 (depends on 10)

The method of claim 10, wherein said binding protein specifically binds to the FXN present in the FXN fusion protein.

### Claim 12 (depends on 10)

The method of claim 10, wherein said binding protein specifically binds to the CPP present in the FXN fusion protein.

### Claim 13 (depends on 12)

The method of claim 12, wherein the FXN fusion protein comprises HIV-TAT (SEQ ID NO: 4) or HIV-TAT+M (SEQ ID NO: 15) and wherein said binding protein specifically binds to the HIV-TAT.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the sample is a tissue sample.

### Claim 15 (depends on 14)

The method of claim 14, wherein the tissue sample comprises a buccal swab.

### Claim 16 (depends on 14)

The method of claim 14, wherein the tissue sample comprises a skin biopsy.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the sample is derived from the blood of the subject.

### Claim 18 (depends on 16)

The method of claim 16, wherein the sample comprises platelets.

### Claim 19 (depends on 16)

The method of claim 16, wherein the sample is a plasma sample.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the method has a precision as measured by % coefficient of variation (% CV) of about 20% or less.

### Claim 21 (depends on 20)

The method of claim 20, wherein the method has a precision as measured by % CV of about 15% or less, about 14% or less, about 13% or less, about 12% or less, about 11% or less, about 10% or less, about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, about 2% or less or about 1% or less.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the method has an accuracy of about 80% to about 120%.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the method is linear for concentration of unprocessed FXN fusion protein ranging from about 0.250 ng/mL to about 25.000 ng/mL.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method of monitoring processing of unprocessed FXN fusion protein in a sample, said method comprising:
obtaining at least two temporally separated samples from said subject; and
determining the amount of unprocessed FXN fusion protein in said temporally separated samples using the method of any one of claims 1-23.

### Claim 25 (depends on 24)

The method of claim 24, wherein the sample is derived from a subject being administered the unprocessed FXN fusion protein.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method of adjusting a dosing schedule for administering unprocessed FXN fusion protein, said method comprising:
obtaining at least two temporally separated samples from the subject being administered unprocessed FXN fusion protein;
determining the amount of unprocessed FXN fusion protein in said temporally separated samples using the method of any one of claims 1-23; and
adjusting the dose of unprocessed FXN fusion protein being administered to the subject and/or dosing frequency of the unprocessed FXN fusion protein being administered to the subject based on the temporal changes in the amount of unprocessed FXN fusion protein observed in the subject.

### Claim 27

A method for determining the amount of unprocessed TAT-GG-FXN (SEQ ID NO: 11) in a sample, said method comprising determining the amount of at least one peptide in said sample by using MS,
wherein said at least one peptide is selected from the group consisting of:
a) a peptide comprising the amino acid sequence SGTLGHPGSLDETTYER (SEQ ID NO: 13); and
b) a peptide comprising the amino acid sequence LGGDLGTYVINK (SEQ ID NO: 14);
wherein said method comprises purifying by immunocapture the unprocessed TAT-GG-FXN from said sample prior to MS;
wherein said immunocapture is carried out using a binding protein comprising an antigen binding domain, wherein said binding protein is capable of binding a TAT protein transduction domain.

### Claim 28 (depends on 27)

The method of claim 27, wherein said sample is obtained from a subject being administered the unprocessed TAT-GG-FXN.

### Claim 29 (depends on 27, 28)

The method of claim 27 or 28, wherein said method comprises the following steps:
a) purifying by immunocapture the unprocessed TAT-GG-FXN from said sample, thereby obtaining immunocaptured complexes comprising the unprocessed TAT-GG-FXN;
b) subjecting said immunocaptured complexes comprising the unprocessed TAT-GG-FXN to digestion by trypsin, thereby producing the peptide comprising SEQ ID NO: 13 and/or the peptide comprising SEQ ID NO: 14; and
c) determining the amount of the peptide comprising SEQ ID NO: 13 and/or the peptide comprising SEQ ID NO: 14 by LC/MS-MS.

### Claim 30 (depends on 29)

The method of claim 29, wherein in part c) the LC comprises reversed-phase chromatography.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the MS-MS comprises monitoring the transition 607.3→669.3 for the peptide comprising SEQ ID NO: 13 and the transition 625.3→794.4 for the peptide comprising SEQ ID NO: 14.

### Claim 32 (depends on 27, 28, 29, 30, 31)

The method of any one of claims 27-31, wherein the sample is a tissue sample.

### Claim 33 (depends on 32)

The method of claim 32, wherein the tissue sample comprises a buccal swab.

### Claim 34 (depends on 32)

The method of claim 32, wherein the tissue sample comprises a skin biopsy.

### Claim 35 (depends on 27, 28, 29, 30, 31)

The method of any one of claims 27-31, wherein the sample is derived from the blood of the subject.

### Claim 36 (depends on 35)

The method of claim 35, wherein the sample comprises platelets.

### Claim 37 (depends on 35)

The method of claim 35, wherein the sample is a plasma sample.

### Claim 38 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 27-37, wherein the method has a precision as measured by % coefficient of variation (% CV) of 20% or less;

### Claim 39 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 27-38, wherein the method has an accuracy of about 80% to about 120%.

### Claim 40 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 27-39, wherein the method is linear for concentrations of unprocessed TAT-GG-FXN ranging from about 0.250 ng/mL to about 25.000 ng/mL.

### Claim 41

A method for determining the amount of FXN in a tissue sample, said method comprising determining the amount of at least one peptide derived from said FXN in said sample by using MS,
wherein said at least one peptide is selected from the group consisting of:
a) a peptide comprising the amino acid sequence SGTLGHPGSLDETTYER (SEQ ID NO: 13); and
b) a peptide comprising the amino acid sequence LGGDLGTYVINK (SEQ ID NO: 14);
wherein the method is characterized by at least one of the following:
the method has a precision as measured by % coefficient of variation (% CV) of 20% or less; and
the method has an accuracy of about 80% to about 120%.

### Claim 42 (depends on 41)

The method of claim 41, wherein said sample is obtained from a subject.

### Claim 43 (depends on 42)

The method of claim 42, wherein said subject is being administered unprocessed FXN fusion protein.

### Claim 44 (depends on 43)

The method of claim 43, wherein said unprocessed FXN fusion protein comprises, from N-terminus to C-terminus, a cell penetrating peptide (CPP), a mitochondrial targeting sequence (MTS) of SEQ ID NO: 3 and FXN.

### Claim 45 (depends on 44)

The method of claim 44, wherein said CPP comprises HIV-TAT (SEQ ID NO: 4) or HIV-TAT+M (SEQ ID NO: 15).

### Claim 46 (depends on 45)

The method of claim 45, wherein said unprocessed FXN fusion protein is TAT-GG-FXN (SEQ ID NO: 11).

### Claim 47 (depends on 41, 42, 43, 44, 45, 46)

The method of any one of claims 41-46, wherein said method comprises purifying by immunocapture the FXN from said sample prior to MS.

### Claim 48 (depends on 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 41-47, wherein said method comprises the following steps:
a) purifying by immunocapture the FXN from said sample, thereby obtaining immunocaptured complexes comprising FXN;
b) subjecting said immunocaptured complexes comprising FXN to digestion by trypsin, thereby producing the peptide comprising SEQ ID NO: 13 and/or the peptide comprising SEQ ID NO: 14; and
c) determining the amount of at least one peptide selected from the group consisting of the peptide comprising SEQ ID NO: 13 and/or the peptide comprising SEQ ID NO: 14 by LC/MS-MS.

### Claim 49 (depends on 48)

The method of claim 48, wherein in part c) the LC comprises reversed-phase chromatography.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein the tandem mass spectrometry (MS-MS) comprises monitoring the transition 607.3→669.3 for the peptide comprising SEQ ID NO: 13 and the transition 625.3→794.4 for the peptide comprising SEQ ID NO: 14.

### Claim 51 (depends on 47, 48, 49, 50)

The method of any one of claims 47-50, wherein the immunocapture is carried out using a binding protein comprising an antigen binding domain that specifically binds FXN.

### Claim 52 (depends on 47, 48, 49, 50)

The method of any one of claims 47-50, wherein said FXN is a part of an FXN fusion protein also comprising HIV-TAT (SEQ ID NO: 4) or HIV-TAT+M (SEQ ID NO: 15) and wherein said binding protein specifically binds the HIV-TAT.

### Claim 53 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 41-52, wherein the tissue sample comprises a buccal swab.

### Claim 54 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 41-52, wherein the tissue sample comprises a skin biopsy.

### Claim 55

A method for determining the amount of FXN in a skin sample, said method comprising determining the amount of at least one peptide derived from said FXN in said skin sample by using MS,
wherein said at least one peptide is selected from the group consisting of:
a) a peptide comprising the amino acid sequence GGMWTLGR (SEQ ID NO: 12);
b) a peptide comprising the amino acid sequence SGTLGHPGSLDETTYER (SEQ ID NO: 13); and
c) a peptide comprising the amino acid sequence LGGDLGTYVINK (SEQ ID NO: 14).

### Claim 56 (depends on 55)

The method of claim 55, wherein said skin sample is obtained from a subject.

### Claim 57 (depends on 56)

The method of claim 56, wherein said subject is being administered unprocessed FXN fusion protein.

### Claim 58 (depends on 57)

The method of claim 57, wherein said unprocessed FXN fusion protein comprises, from N-terminus to C-terminus, a cell penetrating peptide (CPP), a mitochondrial targeting sequence (MTS) of SEQ ID NO: 3 and FXN.

### Claim 59 (depends on 58)

The method of claim 58, wherein said CPP comprises HIV-TAT (SEQ ID NO: 4) or HIV-TAT+M (SEQ ID NO: 15).

### Claim 60 (depends on 59)

The method of claim 59, wherein said unprocessed FXN fusion protein is TAT-GG-FXN (SEQ ID NO: 11).

### Claim 61 (depends on 55, 56, 57, 58, 59, 60)

The method of any one of claims 55-60, wherein said method comprises purifying by immunocapture the FXN from said skin sample prior to MS.

### Claim 62 (depends on 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 55-61, wherein said method comprises the following steps:
a) purifying by immunocapture FXN from said skin sample, thereby obtaining immunocaptured complexes comprising FXN;
b) subjecting said immunocaptured complexes comprising FXN to digestion by trypsin, thereby producing the peptide comprising SEQ ID NO: 12 and/or the peptide comprising SEQ ID NO: 13 and/or the peptide comprising SEQ ID NO: 14; and
c) determining the amount of at least one peptide selected from the group consisting of the peptide comprising SEQ ID NO: 12 and/or the peptide comprising SEQ ID NO: 13 and/or the peptide comprising SEQ ID NO: 14 by LC/MS-MS.

### Claim 63 (depends on 61, 62)

The method of any one of claims 61-62, wherein said immunocapture is carried out using a binding protein comprising an antigen binding domain that specifically binds FXN.

### Claim 64 (depends on 61, 62, 63)

The method of any one of claims 61-63, wherein said FXN is a part of an FXN fusion protein also comprising HIV-TAT (SEQ ID NO: 4) or HIV-TAT+M (SEQ ID NO: 15) and wherein said binding protein specifically binds the HIV-TAT.
